The status of gene therapy for brain tumors

Bibliography

• LOUIS DN, POMEROY SL, CAIRNCROSS JG: Focus on central nervous system neoplasia. Cancer Cell (2002) 1(2):125-128.
   PubMed Web of Science ®Google Scholar
• STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
   PubMed Web of Science ®Google Scholar
• KLEIHUES P, CAVENEE WK: Pathology and Genetics of Tumors of the Nervous System. Kleihues P, Cavenee WK (Eds), International Agency for Research on Cancer, Lyon, France (1997).
   Google Scholar
• KIRSCH M, SCHACKERT G, BLACK PM: Anti-angiogenic treatment strategies for malignant brain tumors. J. Neurooncol. (2000) 50(1-2):149-163.
   PubMed Web of Science ®Google Scholar
• JENDROSSEK V, BELKA C, BAMBERG M: Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Investig. Drugs (2003) 12(12):1899-1924.
   PubMed Web of Science ®Google Scholar
• EHTESHAM M, BLACK KL, YU JS: Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control (2004) 11(3):192-207.
   PubMedGoogle Scholar
• GUERIN C, OLIVI A, WEINGART JD, LAWSON HC, BREM H: Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs (2004) 22(1):27-37.
   PubMed Web of Science ®Google Scholar
• LAM PY, BREAKEFIELD XO: Potential of gene therapy for brain tumors. Hum. Mol. Genet. (2001) 10(7):777-787.
   PubMed Web of Science ®Google Scholar
• CHIOCCA EA, AGHI M, FULCI G: Viral therapy for glioblastoma. Cancer J. (2003) 9(3):167-179.
   PubMed Web of Science ®Google Scholar
• AGHI M, RABKIN S: Viral vectors as therapeutic agents for glioblastoma. Curr. Opin. Mol. Ther. (2005) 7(5):419-430.
   PubMed Web of Science ®Google Scholar
• ICHIMURA K, BOLIN MB, GOIKE HM, SCHMIDT EE, MOSHREF A, COLLINS VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. (2000) 60(2):417-424.
   PubMed Web of Science ®Google Scholar
• FULCI G, LABUHN M, MAIER D et al.: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene (2000) 19(33):3816-3822.
   PubMed Web of Science ®Google Scholar
• YAZAWA K, FUJIMORI M, AMANO J et al.: Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. (2000) 7(2):269-274.
   PubMed Web of Science ®Google Scholar
• AGRAWAL N, BETTEGOWDA C, CHEONG I et al.: Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA (2004) 101(42):15172-15177.
   PubMed Web of Science ®Google Scholar
• VASSAUX G, NITCHEU J, JEZZARD S, LEMOINE NR: Bacterial gene therapy strategies. J. Pathol. (2006) 208(2):290-298.
   PubMed Web of Science ®Google Scholar
• ABOODY KS, BROWN A, RAINOV NG et al.: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. USA (2000) 97(23):12846-12851.
   PubMed Web of Science ®Google Scholar
• GLASS R, SYNOWITZ M, KRONENBERG G et al.: Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J. Neurosci. (2005) 25(10):2637-2646.
   PubMed Web of Science ®Google Scholar
• BENEDETTI S, PIROLA B, POLLO B et al.: Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. (2000) 6(4):447-450.
   PubMed Web of Science ®Google Scholar
• YOSHIDA J, MIZUNO M: Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J. Neurooncol. (2003) 65(3):261-267.
   PubMed Web of Science ®Google Scholar
• VOGES J, RESZKA R, GOSSMANN A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. (2003) 54(4):479-487.
   PubMed Web of Science ®Google Scholar
• MIZUNO M, YOSHIDA J: [Gene therapy for malignant glioma]. Nippon Rinsho (2005) 63(3):469-475.
   PubMedGoogle Scholar
• RAINOV NG, REN H: Clinical trials with retrovirus mediated gene therapy-what have we learned? J. Neurooncol. (2003) 65(3):227-236.
   PubMed Web of Science ®Google Scholar
• VECIL GG, LANG FF: Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. (2003) 65(3):237-246.
   PubMed Web of Science ®Google Scholar
• INOUE R, MOGHADDAM KA, RANASINGHE M, SAEKI Y, CHIOCCA EA, WADE-MARTINS R: Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther. (2004) 11(15):1195-1204.
   PubMed Web of Science ®Google Scholar
• REINBLATT M, PIN RH, BOWERS WJ, FEDEROFF HJ, FONG Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol. (2005) 12(12):1025-1036.
   PubMed Web of Science ®Google Scholar
• SAYDAM O, GLAUSER DL, HEID I et al.: Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol. Ther. (2005) 12(5):803-812.
   Google Scholar
• LI C, BOWLES DE, VAN DYKE T, SAMULSKI RJ: Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. (2005) 12(12):913-925.
   PubMed Web of Science ®Google Scholar
• LINK N, AUBEL C, KELM JM et al.: Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles. Nucleic Acids Res. (2006) 34(2):e16.
   PubMed Web of Science ®Google Scholar
• KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. (2001) 7(7):781-787.
   Google Scholar
• FULCI G, CHIOCCA EA: Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front. Biosci. (2003) 8:e346-e360.
   Google Scholar
• AGHI M, MARTUZA RL: Oncolytic viral therapies – the clinical experience. Oncogene (2005) 24(52):7802-7816.
   PubMed Web of Science ®Google Scholar
• COLE C, QIAO J, KOTTKE T et al.: Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med. (2005) 11(10):1073-1081.
   PubMed Web of Science ®Google Scholar
• KOMAROVA S, KAWAKAMI Y, STOFF-KHALILI MA, CURIEL DT, PEREBOEVA L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. (2006) 5(3):755-766.
   PubMed Web of Science ®Google Scholar
• THORNE SH, NEGRIN RS, CONTAG CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311(5768):1780-1784.
   PubMed Web of Science ®Google Scholar
• POST DE, FULCI G, CHIOCCA EA, VAN MEIR EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. (2004) 4(1):41-51.
   Google Scholar
• DONG JY, WORARATANADHARM J: Gene therapy vector design strategies for the treatment of cancer. Future Oncol. (2005) 1(3):361-373.
   PubMedGoogle Scholar
• LAGE H: Potential applications of RNA interference technology in the treatment of cancer. Future Oncol. (2005) 1(1):103-113.
   PubMedGoogle Scholar
• IZQUIERDO M, MARTIN V, DE FELIPE P et al.: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. (1996) 3(6):491-495.
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. (1997) 3(12):1354-1361.
   PubMed Web of Science ®Google Scholar
• KLATZMANN D, VALERY CA, BENSIMON G et al.: A Phase I/II study of herpes simplex virus type 1 thymidine kinase ‘suicide’ gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. (1998) 9(17):2595-2604.
   PubMed Web of Science ®Google Scholar
• SHAND N, WEBER F, MARIANI L et al.: A Phase I-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10(14):2325-2335.
   PubMed Web of Science ®Google Scholar
• ADACHI N, KONU DL, FREI K, YONEKAWA Y: [The HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme]. No Shinkei Geka (2000) 28(10):865-871.
   PubMedGoogle Scholar
• HARSH GR, DEISBOECK TS, LOUIS DN et al.: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg. (2000) 92(5):804-811.
   PubMed Web of Science ®Google Scholar
• PACKER RJ, RAFFEL C, VILLABLANCA JG et al.: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. (2000) 92(2):249-254.
   PubMed Web of Science ®Google Scholar
• RAINOV NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11(17):2389-2401.
   PubMed Web of Science ®Google Scholar
• PALU G, CAVAGGIONI A, CALVI P et al.: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. (1999) 6(3):330-337.
   PubMed Web of Science ®Google Scholar
• COLOMBO F, BARZON L, FRANCHIN E et al.: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. (2005) 12(10):835-848.
   PubMed Web of Science ®Google Scholar
• SANDMAIR AM, LOIMAS S, PURANEN P et al.: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. (2000) 11(16):2197-2205.
   PubMed Web of Science ®Google Scholar
• TRASK TW, TRASK RP, AGUILAR-CORDOVA E et al.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. (2000) 1(2):195-203.
   Google Scholar
• GERMANO IM, FABLE J, GULTEKIN SH, SILVERS A: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. (2003) 65(3):279-289.
   PubMed Web of Science ®Google Scholar
• LANG FF, BRUNER JM, FULLER GN et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. (2003) 21(13):2508-2518.
   PubMed Web of Science ®Google Scholar
• IMMONEN A, VAPALAHTI M, TYYNELA K et al.: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. (2004) 10(5):967-972.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7(10):867-874.
   PubMed Web of Science ®Google Scholar
• RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7(10):859-866.
   PubMed Web of Science ®Google Scholar
• CHIOCCA EA, ABBED KM, TATTER S et al.: A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. (2004) 10(5):958-966.
   PubMed Web of Science ®Google Scholar
• FREEMAN AI, ZAKAY-RONES Z, GOMORI JM et al.: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. (2006) 13(1):221-228.
   PubMed Web of Science ®Google Scholar
• PUUMALAINEN AM, VAPALAHTI M, AGRAWAL RS et al.: Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. (1998) 9(12):1769-1774.
   PubMed Web of Science ®Google Scholar
• NESTLER U, WAKIMOTO H, SILLER-LOPEZ F et al.: The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J. Neurooncol. (2004) 67(1-2):177-188.
   PubMed Web of Science ®Google Scholar
• JIANG C, WECHUCK JB, GOINS WF et al.: Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J. Virol. (2004) 78(17):8994-9006.
   PubMed Web of Science ®Google Scholar
• KASAI K, SAEKI Y: DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr. Gene Ther. (2006) 6(3):303-314.
   Google Scholar
• CHEN MY, HOFFER A, MORRISON PF et al.: Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. (2005) 103(2):311-319.
   PubMed Web of Science ®Google Scholar
• SAITO R, KRAUZE MT, NOBLE CO et al.: Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J. Neurosci. Methods (2006) 154(1-2):225-232.
   PubMed Web of Science ®Google Scholar
• SAITO R, KRAUZE MT, BRINGAS JR et al.: Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. (2005) 196(2):381-389.
   PubMed Web of Science ®Google Scholar
• OSHIRO EM, VIOLA JJ, OLDFIELD EH et al.: Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther. (1995) 2(2):87-95.
   PubMed Web of Science ®Google Scholar
• DRIESSE MJ, ESANDI MC, KROS JM et al.: Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther. (2000) 7(16):1401-1409.
   PubMed Web of Science ®Google Scholar
• CHIRMULE N, PROPERT K, MAGOSIN S, QIAN Y, QIAN R, WILSON J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. (1999) 6(9):1574-1583.
   PubMed Web of Science ®Google Scholar
• WAKIMOTO H, JOHNSON PR, KNIPE DM, CHIOCCA EA: Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. (2003) 10(11):983-990.
   PubMed Web of Science ®Google Scholar
• NILAVER G, MULDOON LL, KROLL RA et al.: Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA (1995) 92(21):9829-9833.
   Google Scholar
• BARNETT FH, RAINOV NG, IKEDA K et al.: Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. (1999) 6(1):14-20.
   PubMed Web of Science ®Google Scholar
• SCHELLINGERHOUT D, BOGDANOV A JR, MARECOS E, SPEAR M, BREAKEFIELD XO, WEISSLEDER R: Mapping the in vivo distribution of herpes simplex virions. Hum. Gene Ther. (1998) 9(11):1543-1549.
   PubMed Web of Science ®Google Scholar
• SCHELLINGERHOUT D, RAINOV NG, BREAKEFIELD XO, WEISSLEDER R: Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. (2000) 7(19):1648-1655.
   PubMed Web of Science ®Google Scholar
• IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. (1999) 5(8):881-887.
   Google Scholar
• IKEDA K, WAKIMOTO H, ICHIKAWA T et al.: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. (2000) 74(10):4765-4775.
   PubMed Web of Science ®Google Scholar
• WAKIMOTO H, IKEDA K, ABE T et al.: The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. (2002) 5(3):275-282.
   Google Scholar
• KURIYAMA N, KURIYAMA H, JULIN CM, LAMBORN KR, ISRAEL MA: Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. (2001) 61(5):1805-1809.
   PubMed Web of Science ®Google Scholar
• MCKEE TD, GRANDI P, MOK W et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. (2006) 66(5):2509-2513.
   PubMed Web of Science ®Google Scholar
• LOWENSTEIN PR: The case for immunosuppression in clinical gene transfer. Mol. Ther. (2005) 12(2):185-186.
   Google Scholar
• FRIEDMAN A, TIAN JP, FULCI G, CHIOCCA EA, WANG J: Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. (2006) 66(4):2314-2319.
   PubMed Web of Science ®Google Scholar
• WAKIMOTO H, FULCI G, TYMINSKI E, CHIOCCA EA: Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide’s enhancement of viral oncolysis. Gene Ther. (2004) 11(2):214-223.
   PubMed Web of Science ®Google Scholar
• FULCI G, BREYMANN L, GIANNI D et al.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA (2006) 103(34):12873-12878.
   Google Scholar
• LAMFERS ML, FULCI G, GIANNI D et al.: Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. (2006) (In Press).
   PubMedGoogle Scholar
• DOUGLAS JT, KIM M, SUMEREL LA, CAREY DE, CURIEL DT: Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. (2001) 61(3):813-817.
   PubMed Web of Science ®Google Scholar
• KASONO K, BLACKWELL JL, DOUGLAS JT et al.: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. (1999) 5(9):2571-2579.
   PubMed Web of Science ®Google Scholar
• ZHOU G, ROIZMAN B: Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J. Virol. (2005) 79(9):5272-5277.
   PubMed Web of Science ®Google Scholar
• CHUNG R, SAEKI Y, CHIOCCA EA: B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. (1999) 73(9):7556-7564.
   PubMed Web of Science ®Google Scholar
• NAKAMURA H, KASUYA H, MULLEN JT et al.: Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. (2002) 109(7):871-882.
   PubMed Web of Science ®Google Scholar
• KASUYA H, PAWLIK TM, MULLEN JT et al.: Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. (2004) 64(7):2561-2567.
   PubMed Web of Science ®Google Scholar
• KAMBARA H, OKANO H, CHIOCCA EA, SAEKI Y: An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. (2005) 65(7):2832-2839.
   PubMed Web of Science ®Google Scholar
• KANAI R, TOMITA H, SHINODA A et al.: Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther. (2006) 13(2):106-116.
   PubMed Web of Science ®Google Scholar
• MOHR I, STERNBERG D, WARD S, LEIB D, MULVEY M, GLUZMAN Y: A herpes simplex virus Type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. (2001) 75(11):5189-5196.
   PubMed Web of Science ®Google Scholar
• TODO T, MARTUZA RL, RABKIN SD, JOHNSON PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA (2001) 98(11):6396-6401.
   Google Scholar
• KO D, HAWKINS L, YU DC: Development of transcriptionally regulated oncolytic adenoviruses. Oncogene (2005) 24(52):7763-7774.
   PubMed Web of Science ®Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373-376.
   PubMed Web of Science ®Google Scholar
• FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19(1):2-12.
   PubMed Web of Science ®Google Scholar
• GOMEZ-MANZANO C, BALAGUE C, ALEMANY R et al.: A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene (2004) 23(10):1821-1828.
   PubMed Web of Science ®Google Scholar
• FARASSATI F, YANG AD, LEE PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. (2001) 3(8):745-750.
   Google Scholar
• SHAH AC, PRICE KH, PARKER JN et al.: Serial passage through human glioma xenografts selects for a deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J. Virol. (2006) 80(15):7308-7315.
   PubMed Web of Science ®Google Scholar
• BOVIATSIS EJ, PARK JS, SENA-ESTEVES M et al.: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. (1994) 54(22):5745-5751.
   PubMed Web of Science ®Google Scholar
• CHASE M, CHUNG RY, CHIOCCA EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. (1998) 16(5):444-448.
   Google Scholar
• TYMINSKI E, LEROY S, TERADA K et al.: Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. (2005) 65(15):6850-6857.
   PubMed Web of Science ®Google Scholar
• AGHI M, RABKIN S, MARTUZA RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl Cancer Inst. (2006) 98(1):38-50.
   PubMed Web of Science ®Google Scholar
• LAMPSON LA: New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J. Neurooncol. (2001) 53(3):275-287.
   PubMed Web of Science ®Google Scholar
• BRINSTER RL, CHEN HY, MESSING A, VAN DYKE T, LEVINE AJ, PALMITER RD: Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 37(2):367-379.
   PubMed Web of Science ®Google Scholar
• CORCORAN RB, SCOTT MP: A mouse model for medulloblastoma and basal cell nevus syndrome. J. Neurooncol. (2001) 53(3):307-318.
   PubMed Web of Science ®Google Scholar
• UHRBOM L, HOLLAND EC: Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. J. Neurooncol. (2001) 53(3):297-305.
   PubMed Web of Science ®Google Scholar
• DING H, GUHA A: Mouse astrocytoma models: embryonic stem cell mediated transgenesis. J. Neurooncol. (2001) 53(3):289-296.
   PubMed Web of Science ®Google Scholar
• EARNEST FT, KELLY PJ, SCHEITHAUER BW et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology (1988) 166(3):823-827.
   PubMed Web of Science ®Google Scholar
• HERHOLZ K, WIENHARD K, HEISS WD: Validity of PET studies in brain tumors. Cerebrovasc. Brain Metab. Rev. (1990) 2(3):240-265.
   PubMedGoogle Scholar
• PRICE P: PET as a potential tool for imaging molecular mechanisms of oncology in man. Trends Mol. Med. (2001) 7(10):442-446.
   PubMed Web of Science ®Google Scholar
• JACOBS AH, DITTMAR C, WINKELER A, GARLIP G, HEISS WD: Molecular imaging of gliomas. Mol. Imaging (2002) 1(4):309-335.
   Google Scholar
• CHO JY, XING S, LIU X et al.: Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. (2000) 7(9):740-749.
   PubMed Web of Science ®Google Scholar
• BOLAND A, RICARD M, OPOLON P et al.: Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. (2000) 60(13):3484-3492.
   PubMed Web of Science ®Google Scholar
• JACOBS A, TJUVAJEV JG, DUBROVIN M et al.: Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. (2001) 61(7):2983-2995.
   PubMed Web of Science ®Google Scholar
• REHEMTULLA A, HALL DE, STEGMAN LD et al.: Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging (2002) 1(1):43-55.
   Google Scholar
• FLOETH FW, AULICH A, LANGEN KJ, BURGER KJ, BOCK WJ, WEBER F: MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. Am. J. Neuroradiol. (2001) 22(8):1517-1527.
   PubMed Web of Science ®Google Scholar
• MORANDI E, ZINGARETTI C, CHIOZZOTTO D et al.: A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett. (2006) 231(1):74-86.
   PubMed Web of Science ®Google Scholar
• HUSSAIN SF, YANG D, SUKI D, GRIMM E, HEIMBERGER AB: Innate immune functions of microglia isolated from human glioma patients. J. Transl. Med. (2006) 4:15.
   PubMedGoogle Scholar
• CONDEELIS J, POLLARD JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124(2):263-266.
   PubMed Web of Science ®Google Scholar